The role of TGF-β in epithelial malignancy and its relevance to the pathogenesis of oral cancer (part II)

Critical Reviews in Oral Biology and Medicine

Volumn 15, Issue 6, 2004, Pages 337-347

  Prime, S S ^a   Davies, M ^a   Pring, M ^a   Paterson, I C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cancer; Epithelial; Oral; TGF

Indexed keywords

BETA CAROTENE; FENRETINIDE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; DNA BINDING PROTEIN; TRANSACTIVATOR PROTEIN;

CARCINOGENESIS; CLINICAL TRIAL; DRUG INHIBITION; EPITHELIUM CELL; HUMAN; LUNG CANCER; LUNG METASTASIS; MESENCHYME CELL; MOUTH CANCER; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR PROMOTION; ANIMAL; CARCINOMA; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MOUTH TUMOR; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 28744453728     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/154411130401500603     Document Type: Review

References (164)

1. Abe T, Ouyang H, Migita T, Kato Y, Kimura M, Shiba K, et al. (1996). The somatic mutation frequency of the transforming growth factor-β receptor type II gene varies widely among different cancers with microsatellite instability. Eur J Surg Oncol 22:474-477.
2. Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, et al. (2000). Inhibition of farnesyltransferase increases TGF-β type II receptor expression and enhances the responsiveness of human cancer cells to TGF-β. Oncogene 19:5525-5533.
3. Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, et al. (2002). Farnesyltransferase inhibitor (L-744,832) restores TGF-β type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Oncogene 21:7883-7890.
4. The Alpha-Tocepherol Beta Carotene Cancer Prevention Study (1994). The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035.
5. Amendt C, Schirmacher P, Weber H, Blessing M (1998). Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17:25-34.
6. Bakin AV, Rinehart C, Tomlinson AK, Arteage CL (2002). P38 mitogen activated protein kinase is required for TGF-β-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115:3193-3206.
7. Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, et al. (2002). Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 62:4690-4695.
8. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A (2002). The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 116:499-511.
9. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E (1990). Suppression of glomerulonephritis by antiserum against transforming growth factor-β1. Nature 346:371-374.
10. Borger DR, Mi Y, Geslani G, Zyzack LL, Batova A, Engin TSW, et al. (2000). Retinoic acid resistance at late stages of papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signaling and is due to loss of sensitivity to transforming growth factor-β. Virology 270:397-407.
11. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM (1997). Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res 57:5564-5570.
12. Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, et al. (2003). Smad7 is a prognostic marker in patients with colorectal cancer. Int J Cancer 104:446-449.
13. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothens AD, Morris RG, et al. (1996). Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12:2641-1249.
14. Caulin C, Scholl FG, Frontelo P, Gamallo C, Quintanilla M (1995). Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-β1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ 6:1027-1035.
15. Chen R-H, Ebner R, Derynck R (1993). Inactivation of type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science 260:1335-1338.
16. Chen T, Yan W, Wells RG, Rimm DL, McNiff J, Leffell D, et al. (2001). Novel inactivating mutations of transforming growth factor-β type I receptor gene in head-and-neck cancer metastases. Int J Cancer 93:653-661.
17. Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, et al. (1998). Determinants of specificity in TGF-β signal transduction. Genes Dev 12:2144-2152.
18. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, et al. (2001). The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7:1267-1278.
19. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S (2003). Links between tumor suppressors: p53 is required for TGF-β gene responses by cooperating with Smads. Cell 113:301-314.
20. Cui W, Kemp CJ, Duffie E, Balmain A, Akhurst RJ (1994). Lack of TGF-β1 expression in benign skin tumors of p53 null mice is prognostic for a high risk of malignant conversion. Cancer Res 54:5831-5836.
21. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, et al. (1996). TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531-542.
22. Dalal BI, Keown PA, Greenberg AH (1993). Immunocytochemical localization of secreted transforming growth factor-β1 to the advancing edge of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143:381-389.
23. Davies M, Prime SS, Stone AM, Heung Y-L, Huntley SP, Matthews JB, et al. (1997). Overexpression of autocrine TGF-β1 suppresses the growth of spindle epithelial cells in vitro and in vivo in the rat 4NQO model of oral carcinogenesis. Int J Cancer 73:68-74.
24. Davies M, Paterson IC, Stone A, Huntley S, Patel V, Curtis R, et al. (1999). Loss of differentiation of 4NQO-induced malignant oral rat keratinocytes correlates with metastatic dissemination and is associated with a reduced cellular response to TGF-β1 and an altered receptor profile. J Oral Path Med 28:397-405.
25. de Caestecker MP, Piek E, Roberts AB (2000). Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 92:1388-1402.
26. Derynck R, Akhurst RJ, Balmain A (2001). TGF-β signaling in tumor suppression and cancer progression. Nature Genet 29:117-129.
27. Downward J (2003). Targeting Ras signaling pathways in cancer therapy. Nature Rev Cancer 3:11-22.
28. Dumont N, Arteaga CL (2002). The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGF-β. Differentiation 70:574-582.
29. Dumont N, Bakin AV, Arteaga CL (2003). Autocrine transforming growth factor-β signaling mediates Smad-independent motility in human cancer cells. J Biol Chem 278:3275-3285.
30. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, et al. (2001). Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61:4222-4228.
31. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doelschman T (1999). Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59:3379-3386.
32. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, et al. (1996). MADR2 maps to 18q21 and encodes a TGF-β regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543-552.
33. Fahey MS, Paterson IC, Stone A, Collier AJ, Heung YLM, Davies M, et al. (1996). Dysregulation of autocrine TGF-β isoform production and ligand responses in human tumor-derived and Ha-ras-transfected keratinocytes and fibroblasts. Br J Cancer 74:1074-1080.
34. Frank CJ, McClatchey KD, Devaney KO, Carey TE (1997). Evidence that loss of chromosome 18q is associated with tumor progression. Cancer Res 57:824-827.
35. Friess H, Yamanaka Y, Buchler M (1993). Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105:1846-1858.
36. Frixen U, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. (1991). E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113:173-185.
37. Gabbert H, Wagner R, Moll R, Gerharz CD (1985). Tumor de-differentiation: an important step in tumor invasion. Clin Exp Metastases 3:257-279.
38. Game SM, Stone A, Matthews JB, Scully C, Prime SS (1991). Differentiation of malignant oral rat keratinocytes reflects changes in EGF and TGF-β receptor expression but not growth factor dependence. Carcinogenesis 12:409-416.
39. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M (1995). Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res 55:3982-3987.
40. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al. (2000). Mutations truncating the EP300 acetylase in human cancers. Nature Genet 24:300-3003.
41. Geng MM, Ellenrieder V, Wallrapp C, Muller-Pillasch F, Sommer G, Adler G, et al. (1999). Use of representational difference analysis to study the effect of TGF-β on the expression profile of a pancreatic cancer cell line. Genes Chromosomes Cancer 26:70-79.
42. Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR, Pierschbacher MD (1997). Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 54:1205-1216.
43. Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, et al. (1993). Loss of expression of TGF-β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 90:6076-6080.
44. Glick AB, Lee MM, Darwiche N, Kulkarni AB, Karlsson S, Yuspa SH (1994). Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 8:2429-2440.
45. Glick AB, Weinberg WC, Wu IH, Quan W, Yuspa SH (1996). Transforming growth factor-beta1 suppresses genomic instability independent of a G1 arrest, p53 and Rb. Cancer Res 56:3645-3650.
46. Go C, He W, Zhong L, Li P, Huang J, Brinkley BR, et al. (2000). Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFbetaRII. Oncogene 19:3623-3631.
47. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE (1998). Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 58:5329-5332.
48. Gotzmann J, Huber H, Thallinger C, Wolschek M, Jansen B, Schulte-Hermann R, et al. (2002). Hepatocytes convert to a fibroblastoid phenotype through the co-operation of TGF-β and Ha-Ras: steps towards invasiveness. J Cell Sci 115:1189-1202.
49. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, et al. (1999). Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 59:320-324.
50. Grunert S, Jechlinger M, Beug H (2003). Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nature Rev Mol Cell Biol 4:657-665.
51. Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, et al. (2002). Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 277:39209-39216.
52. Hahm KB, Lee KM, Kim YB, Hong WS, Lee WH, Han SU, et al. (2002). Conditional loss of TGF-beta signaling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharmacol Ther 16:115-127.
53. Hahn SA, Seymour AB, Hoque AT, Schutte M, da Costa LT, Redstron MS, et al. (1995). Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 55:4670-4675.
54. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353.
55. Han SK, Kim HT, Seong DH, Kim YS, Park YS, Bang YJ, et al. (2004). Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 23:1333-1341.
56. Hasina R, Matsumoto K, Matsumoto-Taniura N, Kato I, Sakuda M, Nakamura T (1999). Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. Br J Cancer 80:1708-1717.
57. Herbert BS, Sanders BG, Kline K (1999). N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells. Nutr Cancer 34:121-132.
58. Hojo M, Morimot T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. (1999). Cyclosporin induces cancer progression by a cell-autonomous mechanism. Nature 397:530-534.
59. Hoteiya T, Hayashi E, Satomura K, Kamata N, Nagayama M (1999). Expression of E-cadherin in oral cancer cell lines and its relationship to invasiveness in SCID mice in vivo. J Oral Path Med 28:107-111.
60. Huang F, Newman E, Theodorescu D, Kerbel RS, Friedman E (1995). Transforming growth factor-β1 (TGF-β1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF-β1 antisense expression plasmid. Cell Growth Differ 6:1635-1642.
61. Huntley SP, Davies M, Matthews JB, Marshall J, Robinson CM, Eveson JW, et al. (2004). Attenuated type II TGF-β receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination. Int J Cancer 110:170-176.
62. Iglesias M, Frontelo P, Gamallo C, Quintanilla M (2000). Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signaling pathway associated with progression to undifferentiated carcinomas. Oncogene 19:4134-4145.
63. Im Y-H, Kim HT, Kim IY, Factor VM, Hahm K-B, Anzano M, et al. (2001). Heterozygous mice for the transforming growth factor-β type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. Cancer Res 61:6665-6668.
64. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, et al. (2002). Ras and TGF-β cooperatively regulate epithelial cell plasticity and metastasis: dissection of signaling pathways. J Cell Biol 156:299-313.
65. Janji B, Melchior C, Gouon V, Vallar L, Kieffer N (1999). Autocrine TGF-β-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype. Int J Cancer 83:255-262.
66. Jennings R, Alsarraj M, Wright KL, Munoz-Antonia T (2001). Regulation of the human transforming growth factor beta type II receptor gene promoter by novel Sp1 sites. Oncogene 20:6899-6909.
67. Jones JW, Raval JR, Beals TF, Worsham MJ, Van Dyke DL, Esclamado RM, et al. (1997). Frequent loss of heterozygosity on chromosome arm 18q in squamous cell carcinomas. Identification of 2 regions of loss - 18q11.1-q12.3 and 18q21.1-q23. Arch Otolaryngol Head Neck Surg 123:610-614.
68. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, et al. (2002). Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277:24571-24578.
69. Kang SH, Bang YJ, Im YH, Yang HK, Lee DA, Lee HS, et al. (1999). Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer. Oncogene 18:7280-7286.
70. Kanzler S, Meyer E, Lohse AW, Schirmacher P, Henninger J, Galle PR, et al. (2001). Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene 20:5015-5024.
71. Kim JH, Shariat SF, Kim IY, Menesses-Diaz A, Tokunaga H, Wheeler TM, et al. (2001). Predictive value of expression of TGF-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 92:1475-1483.
72. Kim SJ, Im YH, Markowitz SD, Bang YJ (2000). Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 11:159-168.
73. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW (1999). The TGF-β signaling inhibitor Smad7 enhances tumori-genicity in pancreatic cancer. Oncogene 18:5363-5672.
74. Knobloch TJ, Lynch MA, Song H, DeGroff VL, Casto BC, Adams EM, et al. (2001). Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers. Mutat Res 479:131-139.
75. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. (1993). Transforming growth factor β null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770-774.
76. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, et al. (1998). The oncoprotein Evi-1 represses TGF-beta signaling by inhibiting Smad3. Nature 394:92-96.
77. La P, Morgan TA, Sykes SM, Mao H, Schnepp RW, Petersen CD, et al. (2003). Fusion proteins of retinoid receptors antagonize TGF-β-induced growth inhibition of lung epithelial cells. Oncogene 22:198-210.
78. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, et al. (2002). Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58-64.
79. Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A, McMahon M, et al. (2000). Raf induces TGF-β production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 14:2610-2622.
80. Logullo AF, Nonogaki S, Miguel RE, Kowalski LP, Nishimoto IN, Pasisni FS, et al. (2003). Transforming growth factor beta 1 (TGF beta 1) expression in head and neck squamous cell carcinoma patients as related to prognosis. J Oral Pathol Med 32:139-145.
81. Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, et al. (1999). The ski oncoprotein interacts with the Smad proteins to repress TGF-beta signaling. Genes Dev 13:2196-2206.
82. Maitra A, Molberg K, Albores-Saavedra J, Lindberg G (2000). Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol 157:1105-1111.
83. waf1 induction are important early events. Cell Growth Differ 7:1291-1304.
84. Marcil I, Stern RS (2001). Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: nested cohort crossover study. Lancet 358:1042-1045.
85. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. (1995). Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338.
86. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, et al. (2001). Invasion and metastasis of a mammary tumor involves TGF-β signaling. Int J Cancer 91:76-82.
87. Medrano EE (2003). Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene 22:3123-3129.
88. Miettinen MJ, Ebner R, Lopez AR, Derynck R (1994). TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 127:2021-2036.
89. Minamoto T, Mai M, Ronai Z (2000). K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas and lung cancers - a review. Cancer Detect Prev 24:1-12.
90. Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, et al. (1999). Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18:3098-3103.
91. Munoz-Antonia T, Reiss M, Jackson R, Antonia S (1996). A mutation of the transforming growth factor type II receptor gene promoter associated with loss of gene expression. Cancer Res 56:4831-4835.
92. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong JM, et al. (1996). p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12:1565-1569.
93. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, et al. (2002). Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109:1551-1559.
94. Muro-Cacho CA, Rosario-Ortiz K, Livingston S, Munoz-Antonia T (2001). Defective transforming growth factor β signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2. Clin Cancer Res 7:1618-1626.
95. Natsugoe S, Xiangming C, Matsumoto M, Okumura H, Nakashima S, Sakita H, et al. (2002). Smad4 and transforming growth factor β1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 8:1838-1842.
96. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E (1996). TGF-β1 and Ha-ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10:2462-2477.
97. Oft M, Heider K-H, Beug H (1998). TGF-β signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8:1243-1252.
98. Oft M, Akhurst RJ, Balmain A (2002). Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 4:487-494.
99. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. (1993). Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 53:1696-1701.
100. Okamoto A, Jiang W, Kim SJ, Spillare EA, Stoner G, Weinstein IB, et al. (1994). Overexpression of cyclin D1 reduces the transforming growth factor-beta (TGF-β) type II receptor and growth inhibition by TGF-β1 in an immortalised human oesophageal epithelial cell line. Proc Natl Acad Sci USA 91:11576-11580.
101. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. (1996). Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155.
102. Oridate N, Lotan D, Xu XC, Hong WK, Lotan R (1996). Differential induction of apoptosis by all trans retinoic acid and N-(4-hydroxyphenyl) retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2:855-863.
103. Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, et al. (2001). Heterogeneous transforming growth factor (TGF)-β unresponsiveness and loss of TGF-β receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res 61:8331-8339.
104. Park B-J, Park J-I, Byun D-S, Park J-H, Chi S-G (2000). Mitogenic conversion of transforming growth factor-β1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res 60:3031-3038.
105. Park JA, Wang E, Kurt RA, Schluter SF, Hersh EM, Akporiaye ET (1997). Expression of antisense transforming growth factor-β1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther 4:42-50.
106. Pasini FS, Brentani MM, Kowalski LP, Federico M (2001). Transforming growth factor beta1, urokinase-type plasminogen activator and urokinase plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck 23:725-732.
107. Paterson IC, Patel V, Sandy JR, Prime SS, Yeudall WA (1995). Effects of transforming growth factor beta-1 on growth regulatory genes in tumor-derived human oral keratinocytes. Br J Cancer 72:922-927.
108. Paterson IC, Eveson JW, Prime SS (1996). Molecular changes in oral cancer reflect ethnic origin and aetiology. Oral Oncol Eur J Cancer 32(B):150-153.
109. Paterson IC, Matthews JB, Huntley S, Robinson CM, Fahey M, Parkinson EK, et al. (2001). Decreased expression of TGF-β cell surface receptors during progression of human oral squamous cell carcinoma. J Pathol 193:458-467.
110. Paterson IC, Davies M, Stone A, Huntley S, Smith E, Pring M, et al. (2002). TGF-β acts as a tumor suppressor of human malignant keratinocytes independently of Smad4 expression and ligand-induced G1 arrest. Oncogene 21:1616-1624.
111. Peinado H, Quintanilla M, Cano A (2003). Transforming growth factor beta 1 induces Snail transcription factor in epithelial cell lines. Mechanisms for epithelial mesenchymal transitions. J Biol Chem 278:21113-21123.
112. Picon A, Gold LI, Wang J, Cohen A, Friedman E (1998). A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta 1. Cancer Epidemiol Biomarkers Prev 7:497-504.
113. Piek E, Moustakas A, Kurisaki A, Heldin C-H, ten Dijke P (1999). TGF-β type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 112:4557-4568.
114. Pierce DF, Gorska AE, Chytil A, Meise KS, Page DL, Coffey RJ, et al. (1995). Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc Natl Acad Sci USA 92:4254-4258.
115. Portella G, Cumming SA, Liddell J, Cui C, Ireland H, Akhurst R, et al. (1998). Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ 9:393-404.
116. Prime SS, Matthews JB, Patel V, Game SM, Donnelly M, Stone A, et al. (1994). TGF-β receptor regulation mediates the response to exogenous ligand but is independent of the degree of cellular differentiation in human oral keratinocytes. Int J Cancer 56:406-412.
117. Rangarajan A, Weinberg RA (2003). Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Rev Cancer 3:952-959.
118. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, et al. (1996). Mad-related genes in the human. Nat Genet 13:347-349.
119. Roberson KM, Penland SN, Padilla GM, Selvan RS, Kim CS, Fine RL, et al. (1997). Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Cell Growth Differ 8:101-111.
120. Roberts AB, Wakefield L (2003). The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 100:8621-8623.
121. Rodriguez C, Huang LJ, Son JK, McKee A, Xiao Z, Lodish HF (2001). Functional cloning of the prot-oncogene brain factor-1 (BF-1) as a Smad-binding antagonist of transforming growth factor signaling. J Biol Chem 276:30224-30230.
122. Roijer E, Moren A, ten Dijke P, Stenman G (1998). Assignment of the Smad7 gene (MADH7) to human chromosome 18q21.1 by fluorescence in situ hybridisation. Cytogenet Cell Genet 81:189-190.
123. Rowland-Goldsmith MA, Maruyama H, Matsuda K, Idezawa T, Ralli M, Ralli S, et al. (2002). Soluble type II transforming growth factor-β receptor attenuates expression of metastases-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 1:161-167.
124. Saha D, Datta PK, Beauchamp RD (2001). Oncogenic Ras represses transforming growth factor-beta/Smad signaling by degrading tumor suppressor Smad4. J Biol Chem 276:29531-29537.
125. Salovaara R, Roth S, Loukola A, Launonen V, Sistonen P, Aviziente E, et al. (2002). Frequent loss of Smad4/DPC4 protein in colorectal cancers. Gut 51:56-59.
126. Schipper J, Frixen U, Behrens J, Unger A, Jahnke K, Birchmeier W (1991). E-cadherin expression in squamous cell carcinomas of the head and neck: invasive correlation with tumor de-differentiation and lymph node metastasis. Cancer Res 51:6328-6337.
127. Schmid P, Itin D, Rufli TH (1996). In situ analysis of transforming growth factor-β (TGF-β1, TGF-β2, TGF-β3) and TGF-β type II receptor expression in basal cell carcinomas. Br J Dermatol 134:1044-1051.
128. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, et al. (1996). DPC4 gene in various tumor types. Cancer Res 56:2527-2530.
129. Seijo ER, Song H, Lynch MA, Jennings R, Qong X, Lazaridis E, et al. (2001). Identification of genetic alterations in the TGF-beta type II receptor gene promoter. Mutat Res 483:19-26.
130. Sekiya T, Adachi S, Kohu K, Yamada T, Higuchi O, Furukawa Y, et al. (2004). Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-β signalling, as a target of the β-catenin pathway in colorectal tumor cells. J Biol Chem 279:6840-6846.
131. Shah AH, Tabayoyong WB, Kundu SD, Kim S-J, Parijs LV, Liu VC, et al. (2002). Suppression of tumor metastases by blockade of transforming growth factor β signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res 62:7135-7138.
132. Shi Y, Hata A, Lo RS, Massagué J, Pavletich NP (1997). Structural basis for mutational inactivation of the tumor suppressor Smad4. Nature 388:87-93.
133. Siegel PM, Massagué J (2003). Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 3:807-819.
134. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J (2003). Transforming growth factor β signaling impairs neu-induced mammary tumorigenesis while promoting pulmonary metastases. Proc Natl Acad Sci USA 100:8430-8435.
135. Steiner MS, Barrack ER (1992). Transforming growth factor-β overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 6:15-25.
136. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K (1999). Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein. Science 286:771-774.
137. Suganuma T, Kawabata M, Ohshima T, Ikeda M-A (2002). Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator. Proc Natl Acad Sci USA 99:13073-13078.
138. Tang B, Bottinger EP, Jakolew SB, Bagnall KM, Mariano J, Anver MR, et al. (1998). Transforming growth factor beta 1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 4:802-807.
139. Tang B, Vu M, Booker T, Santner S, Miller FR, Anver M, et al. (2003). TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112:1116-1124.
140. Tian F, DaCosta Byfield S, Parks WT, Yoo S, Felici A, Tang B, et al. (2003). Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 63:8284-8292.
141. Tremain R, Marko M, Kinnimulki V, Ueno H, Bottinger E, Glick A (2000). Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras. Oncogene 19:1698-1709.
142. Van Dyke DL, Worsham MJ, Benninger MS, Krause CJ, Baker SR, Wolf GT, et al. (1994). Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 9:192-206.
143. Venkatasubbarao K, Ammanamanchi S, Brattain MG, Mimari D, Freeman JW (2001). Reversion of transcriptional repression of Sp1 by 5 aza-2′ deoxycytidine restores TGF-beta type II receptor expression in the pancreatic cancer cell line MIA PaCa-2. Cancer Res 61:6239-6247.
144. Vincent F, Ke Y, Stoner GD, Hagiwara K, Demetrik DJ, Bennett WP (1996). Mutation analysis of the TGF-β type II receptor in sporadic human cancer of the pancreas, liver, breast. Biochem Biophys Res Commun 223:561-564.
145. Wakatsuki S-J, Watanabe R, Saito K, Saito T, Katagiri A, Sato S, et al. (1996). Loss of human E-cadherin (ECD) correlated with invasiveness of transitional cell cancer in the renal pelvis, ureter and urinary bladder. Cancer Lett 103:11-17.
146. Wang D, Song HJ, Evans JA, Lang JC, Schuller DE, Weghorst CM (1997). Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis 18:2285-2290.
147. Welch DR, Fabra A, Nakajima M (1990). Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87:7678-7682.
148. Wu SP, Sun LZ, Willson JK, Humphrey L, Kerbel R, Brattain MG (1993). Repression of autocrine transforming growth factor β1 and β2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ 4:115-123.
149. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, et al. (2002). Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 62:497-505.
150. Xu J, Attisano L (2000). Mutations in the tumor suppressors of Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 97:4820-4825.
151. Yakymovych I, Engstrom U, Grimsby S, Heldin C-H, Souchelnytskyi S (2002). Inhibition of transforming growth factor-β signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF-β type I receptor kinase. Biochemistry 41:11000-11007.
152. Yan W, Vellucci F, Reiss M (2000). Smad protein expression and activation in transforming growth factor-β refractory human squamous cell carcinoma cells. Oncol Res 12:157-167.
153. Yan Z, Deng X, Friedman E (2001). Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-β receptor III. J Biol Chem 276:1555-1563.
154. Yang H, Kyo S, Takatura M, Sun L (2001). Autocrine transforming growth factor beta suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells. Cell Growth Differ 12:119-127.
155. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, et al (2002). Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109:1607-1615.
156. Yi JY, Hur KC, Lee E, Jin YJ, Arteaga CL, Son YS (2002). TGF-β1-mediated epithelial to mesenchymal transition is accompanied by invasion in the SiHa cell line. Eur J Cell Biol 81:457-468.
157. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. (1999). TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206.
158. Yingling JM, Wang XF, Bassing CH (1995). Signaling by the transforming growth factor-β receptors. Biochim Biophys Acta 1242:115-136.
159. Yokoyama K, Kamata N, Fujimoto R, Tsutsumi S, Tomonari M, Taki M, et al. (2003). Increased invasion and matrix metalloproteinase-2 expression by Snail-induced mesenchymal transition in squamous cell carcinomas. Int J Oncol 22:891-898.
160. Zavadil J, Bitzer M, Liang D, Yang Y-C, Massimi A, Kneitz S, et al. (2001). Genetic programs of epithelial cell plasticity directed by transforming growth factor-β. Proc Natl Acad Sci USA 98:6686-6691.
161. Zhao J, Buick RN (1995). Regulation of transforming growth factor beta receptors in H-ras oncogene transformed rat intestinal epithelial cells. Cancer Res 55:61881-61888.
162. Zhao S, Venkatasubbarao K, Li S, Freeman JW (2003). Requirement for a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor β type II receptor expression in human pancreatic cancer cells. Cancer Res 63:2624-2630.
163. Zhu Y, Richardson JA, Parada LF, Graff JM (1998). Smad3 mutant mice develop metastatic colorectal cancer. Cell 94:703-714.
164. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS (2001). Association between the T29 > C polymorphism in the transforming growth factor beta 1 gene and breast cancer among elderly white women: the study of osteoporotic women. J Am Med Assoc 285:2859-2863.